Skip to main content
Novo NordiskIn development

Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The...

Source: Autobound Signal API · 94 signals tracked for Novo Nordisk · updated

Get Novo Nordisk's live signals in Claude or ChatGPT, or by API

AskWhat changed at Novo Nordisk this week? Use Autobound signals for novonordisk.com.

What happened

Novo Nordisk evaluated the safety and efficacy of investigational once-weekly semaglutide injection in children aged 6 to under 12 years with obesity in the phase 3 STEP Young trial.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

PLAINSBORO, N.J. and BAGSVÃRD, Denmark, Nov. 16, 2026 /PRNewswire/ -- Today, Novo Nordisk shared primary results from the phase 3 STEP Young trial evaluating the safety and efficacy of investigational once-weekly semaglutide injection, with a maximum dose of 1.7 mg or 2.4 mg based on baseline body weight, in combination with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years with obesity. 1 The results were presented during a scientific symposium at ObesityWeek ® 2026 and simultaneously published in The New England Journal of Medicine. 1,3 "Severe obesity can profoundly affect a child's physical health, emotional well-being, and daily life. This chronic disease also increases the risk of many obesity-related complications that can emerge early and persist into adulthood," said Ania M. Jastreboff, MD, PhD, Professor of Medicine (Endocrinology) and Pediatrics (Pediatric Endocrinology) at Yale School of Medicine and Director of the Yale Obesity Research Center (Y-Weight). "Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child's trajectory back towards one of improving weight related health." In the STEP Young trial, more than 85% of the children had class II or III severe obesity at...

Keep reading with a free account

The rest of this article, and every signal for Novo Nordisk, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
semaglutide injection
Takes effect
Nov 16, 2026
Location
Plainsboro, New Jersey, United States

The full record

From the Signal API record

Topics and mentions

Product tags

  • general technology
  • medical

Extraction

Confidence
90%
Detected
Nov 16, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Novo Nordisk and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novo Nordisk this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/4692106a-a10d-6584-8165-45e7004d383d returns this record as JSON. POST /v1/companies/enrich returns every signal for novonordisk.com.

{
  "signal_id": "4692106a-a10d-6584-8165-45e7004d383d",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-16T15:00:00+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/wegovy-resulted-in-a-bmi-reduction-of-10-or-more-in-almost-80-of-children-with-obesity-aged-6-to-under-12-compared-to-0-with-placebo-in-step-young-trial-published-in-the-new-england-journal-of-medicine-302940442.html",
    "title": "Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine",
    "excerpt": "PLAINSBORO, N.J. and BAGSVÃRD, Denmark , Nov. 16, 2026 /PRNewswire/ -- Today, Novo Nordisk shared primary results from the phase 3 STEP Young trial evaluating the safety and efficacy of investigational once-weekly semaglutide injection, with a maximum dose of 1.7 mg or 2.4 mg based on baseline body weight, in combination with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years with obesity. 1 The results were presented during a scientific symposium at ObesityWeek ® 2026 and simultaneously published in The New England Journal of Medicine . 1,3 \"Severe obesity can profoundly affect a child's physical health, emotional well-being, and daily life. This chronic disease also increases the risk of many obesity-related complications that can emerge early and persist into adulthood,\" said Ania M. Jastreboff, MD, PhD, Professor of Medicine (Endocrinology) and Pediatrics (Pediatric Endocrinology) at Yale School of Medicine and Director of the Yale Obesity Research Center (Y-Weight). \"Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child's trajectory back towards one of improving weight related health.\" In the STEP Young trial, more than 85% of the children had class II or III severe obesity at...",
    "product": "semaglutide injection",
    "summary": "Novo Nordisk evaluated the safety and efficacy of investigational once-weekly semaglutide injection in children aged 6 to under 12 years with obesity in the phase 3 STEP Young trial.",
    "location": "Plainsboro, New Jersey, United States",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS428726/NY80976LOGO.jpg?id=OA3077636&p=facebook",
    "confidence": 0.9,
    "product_data": {
      "name": "semaglutide injection",
      "full_text": "investigational once-weekly semaglutide injection",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-11-16T15:00:00Z",
    "location_data": [
      {
        "city": "Plainsboro",
        "state": "New Jersey",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-16",
    "article_sentence": "Today, Novo Nordisk shared primary results from the phase 3 STEP Young trial evaluating the safety and efficacy of investigational once-weekly semaglutide injection, with a maximum dose of 1.7 mg or 2.4 mg based on baseline body weight, in combination with a reduced-calorie diet and increased physical activity in children aged 6 to under 12 years with obesity."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.